Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma (ALPMF)
:ALPMF
Total Valuation
Astellas Pharma has a market cap or net worth of $17.35B. The enterprise value is $3.14T.
Market Cap$17.35B
Enterprise Value$3.14T
Share Statistics
Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,809,663,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Astellas Pharma’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 16.27%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)16.27%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee129.61M
Profits Per Employee3.44M
Employee Count14,754
Asset Turnover0.57
Inventory Turnover1.63
Valuation Ratios
The current PE Ratio of Astellas Pharma is 51.03. Astellas Pharma’s PEG ratio is 0.26.
PE Ratio51.03
PS Ratio0.00
PB Ratio1.65
Price to Fair Value1.71
Price to FCF15.45
Price to Operating Cash Flow12.57
PEG Ratio0.26
Income Statement
In the last 12 months, Astellas Pharma had revenue of 1.91T and earned 50.75B in profits. Earnings per share was 28.35.
Revenue1.91T
Gross Profit1.43T
Operating Income255.67B
Pretax Income31.50B
Net Income50.75B
EBITDA248.30B
Earnings Per Share (EPS)28.35
Cash Flow
In the last 12 months, operating cash flow was 198.77B and capital expenditures -37.00B, giving a free cash flow of 161.76B billion.
Operating Cash Flow198.77B
Free Cash Flow161.76B
Free Cash Flow per Share89.39
Dividends & Yields
Astellas Pharma pays an annual dividend of $0.257, resulting in a dividend yield of 5.06%
Dividend Per Share$0.257
Dividend Yield5.06%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.20
52-Week Price Change1.36%
50-Day Moving Average9.54
200-Day Moving Average10.17
Relative Strength Index (RSI)51.36
Average Volume (3m)1.51K
Important Dates
Astellas Pharma upcoming earnings date is Jul 30, 2025, TBA Not Confirmed.
Last Earnings DateApr 25, 2025
Next Earnings DateJul 30, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Astellas Pharma as a current ratio of 1.13, with Debt / Equity ratio of 54.94%
Current Ratio1.13
Quick Ratio0.85
Debt to Market Cap0.32
Net Debt to EBITDA2.59
Interest Coverage Ratio14.46
Taxes
In the past 12 months, Astellas Pharma has paid -19.51B in taxes.
Income Tax-19.51B
Effective Tax Rate-0.62
Enterprise Valuation
Astellas Pharma EV to EBITDA ratio is 13.02, with an EV/FCF ratio of 19.64.
EV to Sales1.69
EV to EBITDA13.02
EV to Free Cash Flow19.64
EV to Operating Cash Flow16.03
Balance Sheet
Astellas Pharma has $188.37B in cash and marketable securities with ¥831.43B in debt, giving a net cash position of $643.05B billion.
Cash & Marketable Securities$188.37B
Total Debt¥831.43B
Net Cash$643.05B
Net Cash Per Share$355.34
Tangible Book Value Per Share-$14.34
Margins
Gross margin is 78.25%, with operating margin of 13.37%, and net profit margin of 2.65%.
Gross Margin78.25%
Operating Margin13.37%
Pretax Margin1.65%
Net Profit Margin2.65%
EBITDA Margin12.98%
EBIT Margin2.57%
Analyst Forecast
The average price target for Astellas Pharma is $11.74, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.74
Price Target Upside21.16% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―